contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      viewerIsFollowing
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
      tags {
        viewerIsFollowing
        id
      }
    }
    ... on Webcast {
      liveTime
      tags {
        viewerIsFollowing
        id
      }
    }
    slug
    ... on CompanyReport {
      tags {
        viewerIsFollowing
        id
      }
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


interim-report-january-september-2024-for-combigene-ab-publ

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Lärkberget is a Swedish investment company. The company's main areas of activity are direct investments in low-risk instruments, investments in listed shares, funds and other liquid asset classes, as well as participation in bridge loans and guarantee commitments, investments in unlisted profitable companies, and reverse acquisitions. Lärkberget is headquartered in Stockholm.

Lärkberget

July – September 2024 • Net sales: TSEK 0 (992). • Other operating revenues: TSEK 793 (173). • Profit from financial items: TSEK -8,959 (-8,403). • Earnings per share: SEK -0.45 (-0.42).January...

<div class="mfn-body">July – September 2024 • Net sales: TSEK 0 (992). • Other operating revenues: TSEK 793 (173). • Profit from financial items: TSEK -8,959 (-8,403). • Earnings per share: SEK -0.45 (-0.42).January – September 2024 • Net sales: TSEK 326 (4,948). • Other operating revenues: TSEK 1,347 (588). • Profit from financial items: TSEK -30,720 (-29,305). • Earnings per share: SEK -1.55 (-1.48). • Cash and cash equivalents: TSEK 76,685 (107,187).Events during the period • CombiGene announces new preclinical research results in the epilepsy project, CG01. • Västra Hamnen takes over as Certified Adviser on 25 August 2024. • The rights to the lipodystrophy project, CGT2, have returned to Lipigon on August 5, 2024, and the project has been terminated.Events after the end of the period • CombiGene initiates measures to extend the liquidity horizon by sharpening the strategic focus on gene therapy and implementing a cost reduction program.</div><div class="mfn-footer mfn-contacts mfn-954154356e40">Contacts<hr>CombiGene AB (publ) Peter Ekolind, CEO Phone: +46 (0)8 35 73 55 peter.ekolind@combigene.com<a rel="noopener" href="https://combigene.com/">www.combigene.com</a> CombiGene AB (publ),&nbsp;Skeppsbron 38, SE-111&nbsp;30&nbsp;Stockholm, Sweden +46-8-357355 <a rel="noopener" href="mailto:info@combigene.com">info@combigene.com</a></div><div class="mfn-footer mfn-about mfn-2840449e81ce">About CombiGene<hr>CombiGene’s vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments.Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties. &nbsp; The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is Västra Hamnen Corporate Finance AB.Sign up&nbsp;<a rel="noopener" href="https://combigene.com/ingeneious/">here</a>&nbsp;to subscribe to Ingeneious News, a newsletter from CombiGene that contains general news and information that is deemed not to have a significant impact on the share price. Ingeneious News is also available at <a rel="noopener" href="https://combigene.com/">combigene.com</a>.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a rel="noopener" href="https://storage.mfn.se/ab95beff-2c9c-41c1-960e-836f012b352d/combigene-q3-2024-eng.pdf" class="mfn-primary">CombiGene Q3 2024 ENG</a></div>